Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): A phase III, randomized, multicentre trial of the italian oncology group for clinical research (GOIRC)

Journal of Immunotherapy

Volumn 37, Issue 9, 2014, Pages 440-447

  Passalacqua, Rodolfo ^a   Caminiti, Caterina ^b   Buti, Sebastiano ^a,c   Porta, Camillo ^d   Camisa, Roberta ^c   Braglia, Luca ^b,e   Tomasello, Gianluca ^a   Vaglio, Augusto ^c   Labianca, Roberto ^f   Rondini, Ermanno ^e   Sabbatini, Roberto ^g   Nastasi, Giuseppe ^h   Artioli, Fabrizio ⁱ   Prati, Andrea ^j   Potenzoni, Michele ^j   Pezzuolo, Debora ^c,k   Oliva, Elena ^c   Alberici, Federico ^c   Buzio, Carlo ^c  

^a CREMONA HOSPITAL   (Italy)

^b Research and Innovation Unit   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h BOLOGNINI HOSPITAL   (Italy)

ⁱ Carpi Hospital   (Italy)

^j Vaio Hospital   (Italy)

^k Hospital of Guastalla   (Italy)

more..

Author keywords

Adjuvant low dose immunotherapy; IL 2 and IFN ; Phase III randomized study; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ADULT; AGE; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CLINICAL EVALUATION; CLINICAL OBSERVATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOXICITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROLOGICAL COMPLICATION; OPEN STUDY; OVERALL SURVIVAL; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RADICAL RESECTION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; REPEATED DRUG DOSE; SKIN MANIFESTATION; THYROID DISEASE; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KIDNEY NEOPLASMS; MIDDLE AGED;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED;

EID: 84916641707     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000055     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Buti S, Bersanelli M, Donini M, et al. Systemic adjuvant therapies in renal cell carcinoma. Oncol Rev. 2012;6:145-152.
3. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer. 1996;77:2560-2566.
4. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19:425-431.
5. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/ Intergroup trial. J Clin Oncol. 2003;21:1214-1222.
6. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133-3140.
7. Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92:843-846.
8. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomized controlled trial. Lancet. 2004;363:594-599.
9. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, openlabel, randomized phase III trial. Lancet. 2008;372:145-154.
10. Aitchison M, Bray CA, Van Poppel H, et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. Eur J Cancer. 2014;50:70-77.
11. Belldegrun AS, Chamie K, Kloepfer P, et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-results and implications for adjuvant clinical trials. J Clin Oncol (Meeting Abstracts). 2013;31:4507.
12. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141, Erratum in: J Clin Oncol. 2005; 23:2877.
13. Meropol NJ, Porter M, Blumenson LE, et al. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res. 1996;2:669-677.
14. Buzio C, De Palma G, Passalacqua R, et al. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer. 1997;76:541-544.
15. Buzio C, Andrulli S, Santi R, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer. 2001;92:2286-2296.
16. Passalacqua R, Buzio C, Buti S, et al. Phase III, randomized, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. Cancer Immunol Immunother. 2010;59:553-561.
17. Johnson BE. Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning. J Natl Cancer Inst. 2003; 95:1422-1424.
18. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559-4566.
19. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;98:2566-2575.
20. Berntsen A, Brimnes MK, thor Straten P, et al. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother. 2010;33:425-434.
21. Liotta F, Gacci M, Frosali F, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011;107:1500-1506.
22. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007;13:2075-2081.
23. deLeeuw RJ, Kost SE, Kakal JA, et al. The prognostic value of FoxP3+ tumour-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18:3022-3029.
24. Porta C, Paglino C, Imarisio I, et al. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer. 2011;2:333-338.
25. Buti S, Rovere RK, Donini M, et al. Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-and interferon-a in 146 patients with renal cell carcinoma. Tumori. 2012;98:45-52.